伴有肾前性氮质血症的晚期和转移性实体瘤死亡病例回顾性分析。
Retrospective Analysis of Mortality Cases in Advanced and Metastatic Solid Tumors With Concurrent Prerenal Azotemia.
机构信息
Division of Hemato-Oncology, Department of Internal Medicine, Chang-Gung Memorial Hospital and Chang-Gung University College of Medicine, Taoyuan, Taiwan, R.O.C.
出版信息
In Vivo. 2020 May-Jun;34(3):1515-1519. doi: 10.21873/invivo.11939.
BACKGROUND/AIM: A retrospective study of cases with metastatic or advanced solid tumors complicated with AKI (acute kidney injury) with prerenal azotemia.
PATIENTS AND METHODS
Criteria included: (1) advanced or metastatic solid tumors that led to mortality; (2) prerenal azotemia identified upon renal function evaluation and (3) BUN to Cr ratio (BCR)≥15. We also compared the outcomes of patients with BCR>20 with those of patients with BCR=15-20.
RESULTS
A total of 218 patients with solid tumors were enrolled. One hundred and forty (64%) and 78 (36%) patients had BCR>20 and 15-20, respectively. Before AKI occurrence, 136 (62%) had thromboembolic complications and 96 (44%) paraneoplastic syndromes. Median survival time was 1 week in all patients. Median survival time was statistically different between the groups with BCR15-20 and BCR>20 (p<0.005, log-rank test).
CONCLUSION
Cancer patients with concurrent AKI and prerenal azotemia carry a very poor prognosis.
背景/目的：回顾性分析合并肾前性氮质血症的转移性或晚期实体瘤伴急性肾损伤（AKI）病例。
患者与方法
纳入标准包括：（1）导致死亡的晚期或转移性实体瘤；（2）肾功能评估时发现肾前性氮质血症；（3）BUN 与 Cr 比值（BCR）≥15。我们还比较了 BCR＞20 与 BCR=15-20 的患者的结局。
结果
共纳入 218 例实体瘤患者。140 例（64%）和 78 例（36%）患者的 BCR＞20 和 15-20。在 AKI 发生前，136 例（62%）有血栓栓塞并发症，96 例（44%）有副肿瘤综合征。所有患者的中位生存时间为 1 周。BCR15-20 与 BCR＞20 组之间的中位生存时间存在统计学差异（p＜0.005，log-rank 检验）。
结论
同时伴有 AKI 和肾前性氮质血症的癌症患者预后极差。
Zotero 插件